ERBB2 and neoplasm: We observed that HER2-DC1 i.t. combined with anti-HER2 antibodies treatment showed enhanced antitumor effects with complete tumor regression in 75% of the treated mice and prolonged survival compared with HER2-DC1 s.c. and anti-HER2 antibodies combination treatment (figure 2A, B).